Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with <i>N</i>-Dimethylnitrosamine-Induced Liver Cirrhosis

Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with <i>N</i>-Dimethylnitrosamine-Induced Liver Cirrhosis

Tofacitinib, a Janus kinase 1 and 3 inhibitor, is used to treat rheumatoid arthritis. It is mainly metabolized by the cytochromes p450 (CYP) 3A1/2 and CYP2C11 in the liver. Chronic inflammation eventually leads to cirrhosis in patients with rheumatoid arthritis. Isosakuranetin (ISN), a component of...

Full description

Bibliographic Details
Main Authors:	Sung Hun Bae, Hyeon Gyeom Choi, So Yeon Park, Sun-Young Chang, Hyoungsu Kim, So Hee Kim
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Pharmaceutics
Subjects:	tofacitinib liver cirrhosis isosakuranetin pharmacokinetics CYP3A1/2 CYP2C11
Online Access:	https://www.mdpi.com/1999-4923/14/12/2684

Similar Items

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats
by: Ji-Sang Lee, et al.
Published: (2021-05-01)

Effects of Hyperlipidemia on the Pharmacokinetics of Tofacitinib, a JAK 1/3 Inhibitor, in Rats
by: Jong Mun Won, et al.
Published: (2023-08-01)

Slower Elimination of Tofacitinib in Acute Renal Failure Rat Models: Contribution of Hepatic Metabolism and Renal Excretion
by: Sung Hun Bae, et al.
Published: (2020-07-01)

Effects of Poncirin, a Citrus Flavonoid and Its Aglycone, Isosakuranetin, on the Gut Microbial Diversity and Metabolomics in Mice
by: Xuedan Cao, et al.
Published: (2022-06-01)

Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and <i>O</i>-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling
by: Hyeon-Cheol Jeong, et al.
Published: (2019-11-01)

Isosakuranetin-5-O-rutinoside: A New Flavanone with Antidepressant Activity Isolated from Salvia elegans Vahl.
by: Manáses González-Cortazar, et al.
Published: (2013-10-01)

Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism
by: Ji Sang Lee, et al.
Published: (2019-07-01)

Exploring the modulatory impact of isosakuranetin on Staphylococcus aureus: Inhibition of sortase A activity and α-haemolysin expression
by: Lili Tian, et al.
Published: (2023-12-01)

Modulation of Rat Hepatic CYP1A and 2C Activity by Honokiol and Magnolol: Differential Effects on Phenacetin and Diclofenac Pharmacokinetics In Vivo
by: Sang-Bum Kim, et al.
Published: (2018-06-01)

Population Pharmacokinetics of Primaquine in the Korean Population
by: Woo-Yul Lee, et al.
Published: (2021-05-01)

Impact of Pomegranate Juice on the Pharmacokinetics of CYP3A4- and CYP2C9-Mediated Drugs Metabolism: A Preclinical and Clinical Review
by: Kenza Mansoor, et al.
Published: (2023-02-01)

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
by: Miriam Saiz-Rodríguez, et al.
Published: (2020-04-01)

Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients
by: Jemal Hussien Ahmed, et al.
Published: (2020-04-01)

Effects of naringenin on the pharmacokinetics of tofacitinib in rats
by: Bo Wang, et al.
Published: (2020-01-01)

Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method
by: Liu X, et al.
Published: (2023-09-01)

The Impact of Baohuoside I on the Metabolism of Tofacitinib in Rats
by: Shi Y, et al.
Published: (2024-03-01)

Simultaneous determination of tofacitinib and its principal metabolite in beagle dog plasma by UPLC-MS/MS and its application in pharmacokinetics
by: Qiong Wang, et al.
Published: (2022-01-01)

Study on consequences for interaction of myricetin with canagliflozin: A special attention to pharmacokinetics and pharmacodynamics of drug
by: Naga Raju Kandukoori, et al.
Published: (2023-01-01)

The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis
by: Quyen Thi Tran, et al.
Published: (2022-07-01)

Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam
by: Pablo Zubiaur, et al.
Published: (2022-11-01)

Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6
by: Lee J, et al.
Published: (2019-05-01)

<i>CYP3A5*3</i> and <i>CYP3A4*22</i> Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach
by: Zeyar Mohammed Ali, et al.
Published: (2023-11-01)

Influence of <i>CYP2C9</i> Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis
by: Yoon-A Park, et al.
Published: (2021-06-01)

CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis
by: Dmitry A. Sychev, et al.
Published: (2022-02-01)

Evaluation of the relationship between polymorphisms in CYP2C19 and the single‐dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study
by: Shuang Zhou, et al.
Published: (2022-06-01)

Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism
by: Josefine Schulz, et al.
Published: (2022-02-01)

Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin
by: Gonzalo Villapalos-García, et al.
Published: (2021-10-01)

Effects of ginkgo leaf tablet on the pharmacokinetics of rosiglitazone in rats and its potential mechanism
by: Xueting Xing, et al.
Published: (2022-12-01)

Population pharmacokinetics model for escitalopram in Chinese psychiatric patients: effect of CYP2C19 and age
by: Shujing Liu, et al.
Published: (2022-07-01)

Descriptors of Cytochrome Inhibitors and Useful Machine Learning Based Methods for the Design of Safer Drugs
by: Tyler C. Beck, et al.
Published: (2021-05-01)

Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects
by: Ji Min Han, et al.
Published: (2020-05-01)

Regulation of X-Ray Irradiation on the Activity and Expression Levels of CYP1A2 and CYP2E1 in Rats
by: Xiang-Yang Li, et al.
Published: (2020-01-01)

Population Pharmacokinetic Modeling of Zaltoprofen in Healthy Adults: Exploring the Dosage Regimen
by: Ji-Hun Jang, et al.
Published: (2023-01-01)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
by: Mirza Bojić, et al.
Published: (2019-09-01)

Effect of hesperetin on the pharmacokinetics of metoprolol succinate in rats
by: Ravindra Babu Pingili, et al.
Published: (2023-01-01)

Tofacitinib
by: Nilgün Şentürk
Published: (2022-04-01)

Physiologically-based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance
by: Kristin eDickschen, et al.
Published: (2012-05-01)

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers
by: Shanshan Nie, et al.
Published: (2022-02-01)

Effect of Bakumondo-to on cytochrome P450 activities in rat liver microsomes
by: Masako Yasuhara, et al.
Published: (2016-04-01)

CYP2C19 and CYP2D6 Genotypes and Metabolizer Status Distribution in a Bulgarian Psychiatric Cohort
by: Hristo Y. Ivanov, et al.
Published: (2022-07-01)